丹红注射液治疗特发性肺纤维化的疗效观察

目的：探讨丹红注射液治疗特发性肺纤维化的临床疗效。方法84例特发性肺纤维化患者，按数字表法随机将其分为对照组（泼尼松治疗）和观察组（泼尼松治疗基础上，加用丹红注射液），每组各42例，治疗6周后，对两组临床疗效、血氧分压及CO弥散量、血清转化生长因子（ TGF）-β1及肺通气量、不良反应，进行观察和比较。结果与对照组相比，观察组治疗的总有效率明显提高（92．9％比71．4％，P＜0.05），观察组治疗后血氧分压（67．57±9．93） mmHg比（51．74±9．21） mmHg]及CO弥散量（18．98±3.44）mL· min^-1·mmHg^-1比（15．83±3．06）mL·min^-1·mmHg^-1]均明显升高（均P＜0．05），观察组治疗后血清TGF-β1水平明显降低（1．15±0．13）μg/L比（3．02±0．28）μg/L]，而肺通气量显著提高（1．85±0.36）L比（1．69±0．30）L]（均P＜0．05）；与对照组相比，观察组不良反应发生率显著降低（4．8％比19．0％， P＜0．05）。结论丹红注射液治疗特发性肺纤维化具有疗效显著、安全性高等特点，能够有效纠正低氧血症，明显改善肺功能，值得临床推广。

The clinical efficacy of Danhong injection for the treatment of idiopathic pulmonary fibrosis

Objective To study the clinical efficacy of Danhong injection for the treatment of idiopathic pul-monary fibrosis.Methods 84 patients with idiopathic pulmonary fibrosis were randomized into the control group （ prednisone treatment） and the observation group （ based on the prednisone treatment, added the Danhong injec-tion）,42 patients per group.The clinical efficacy,oxygen partial pressure and CO diffusing capacity,the TGF-β1 in the serum and pulmonary ventilation in the two groups were observed and compared after 6-week treatment. Results Compared with the control group, the total effective rate was significantly increased （ 92.9% vs 71.4%） in the observed group（P〈0.05）;compared with the control group,the oxygen partial pressure （67.57 ±9.93） vs （51.74 ±9.21）]mmHg and CO diffusing capacity（18.98 ±3.44） vs （15.83 ±3.06）]mL/（min· mmHg） were obviously increased in the observed group after treatment（ P〈0.05）;compared with the control group,the content of TGF-β1 in the serum was significantly reduced （1.15 ±0.13） vs （3.02 ±0.28）]μg/L and the pulmonary ventila-tion （1.85 ±0.36） vs （1.69 ±0.30）]L was obviously increased in the observed group after treatment（P〈0.05）;compared with the control group,the incidence of adverse reactions was obviously reduced （4.8%vs 19.0%） in the observed group（P〈0.05）.Conclusion The treatment of Danhong injection for the idiopathic pulmonary fibrosis has the significant efficacy and high safety,can effectively correct th hypoxemia,significantly improve the lung function, which is worthy of clinical promotion.